[1] Schuleri KH, Boyle AJ, Hare JM.Mesenchymal stem cells for cardiac regenerative therapy.Handb Exp Pharmacol. 2007; (180):195-218. [2] Deda H, Inci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009;11(1):18-25. [3] Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, et al. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients.Cytotherapy. 2009; 11(1):26-34. . [4] Taupin P.OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr OpinInvestig Drugs. 2006;7(5):473-481. [5] Abdi R, Fiorina P, Adra CN, et al. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes.Diabetes. 2008;57(7):1759-1767. [6] Yoshikawa T, Mitsuno H, Nonaka I, et al. Wound therapy by marrow mesenchymal cell transplantation.Plast Reconstr Surg. 2008;121(3):860-877. [7] Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.Scand J Immunol. 2003;57(1): 11-20. [8] Aggarwal S, Pittenger MF.Human mesenchymal stem cells modulate allogeneic immune cell responses.Blood. 2005; 105(4):1815-1822. [9] Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells.Blood. 2005;105(10):4120-4126. [10] Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.Blood. 2005;105(5):2214-2219. [11] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions.Blood. 2006;107(1):367-372. [12] Chan JL, Tang KC, Patel AP, et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.Blood. 2006; 107(12):4817-4824. [13] Stagg J, Pommey S, Eliopoulos N, et al. Interferon-gamma- stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell.Blood. 2006;107(6): 2570-2577. [14] Stagg J.Immune regulation by mesenchymal stem cells: two sides to the coin.Tissue Antigens. 2007;69(1):1-9. [15] Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.Blood. 2006;108(6):2114-2120. [16] 郝贵亮,王立斌,陈冬梅,等.母体和胎儿来源的人胎盘间充质干细胞抑制小鼠皮肤移植免疫排斥作用的比较[J].细胞与分子免疫学杂志,2015,31(5):609-614.[17] 马晓娜,刘婷,金毅然,等.母体来源人胎盘间充质细胞的分离培养及其分化能力的研究[J].中国医药指南,2013,11(34):3-5.[18] Syková E, Jendelová P, Urdzíková L, et al. Bone marrow stem cells and polymer hydrogels--two strategies for spinal cord injury repair.Cell Mol Neurobiol. 2006;26(7-8):1113-1129. [19] Satija NK, Singh VK, Verma YK, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med. 2009;13(11-12):4385-4402. [20] Patel DM, Shah J, Srivastava AS.Therapeutic potential of mesenchymal stem cells in regenerative medicine.Stem Cells Int. 2013;2013:496218. [21] Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells.Stem Cells. 2008;26(2):300-311. [22] Kadam S, Muthyala S, Nair P, et al. Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes.Rev Diabet Stud. 2010;7(2):168-182. [23] Lu GH, Zhang SZ, Chen Q, et al. Isolation and multipotent differentiation of human decidua basalis-derived mesenchymal stem cells. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31(2):262-265. [24] Miao Z, Jin J, Chen L, et al. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells.Cell Biol Int. 2006;30(9):681-687. [25] 张红艳,杨乃龙.胎盘来源间充质干细胞的生物学特征[J].中国组织工程研究,2010,14(40):7535-7538.[26] Alviano F, Fossati V, Marchionni C, et al. Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro.BMC Dev Biol. 2007;7:11. [27] Wolbank S, Peterbauer A, Fahrner M, et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue.Tissue Eng. 2007;13(6):1173-1183. [28] Portmann-Lanz CB, Schoeberlein A, Portmann R, et al. Turning placenta into brain: placental mesenchymal stem cells differentiate into neurons and oligodendrocytes.Am J Obstet Gynecol. 2010;202(3):294. e1-294. e11. [29] Ventura C, Cantoni S, Bianchi F, et al. Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts.J Biol Chem. 2007;282(19):14243-14252. [30] 李治,赵伟,刘伟,等.玻璃酸钠及胎盘间充质干细胞和诱导的软骨细胞膝关节腔内注射:修复膝骨关节炎[J].中国组织工程研究, 2014,18(50):8140-8146.[31] Li Z, Qin H, Feng Z, et al. Human umbilical cord mesenchymal stem cell-loaded amniotic membrane for the repair of radial nerve injury.Neural Regen Res. 2013; 8(36): 3441-3448. [32] Ercal P, Pekozer GG, Gumru OZ, et al. Influence of STRO-1 selection on osteogenic potential of human tooth germ derived mesenchymal stem cells.Arch Oral Biol. 2017; 82:293-301. [33] Najar M, Crompot E, van Grunsven LA, et al. Aldehyde Dehydrogenase Activity in Adipose Tissue: Isolation and Gene Expression Profile of Distinct Sub-population of Mesenchymal Stromal Cells.Stem Cell Rev. 2018; 14(4): 599-611. [34] Lee HT, Chang HT, Lee S, et al. Role of IGF1R(+) MSCs in modulating neuroplasticity via CXCR4 cross-interaction.Sci Rep. 2016;6:32595. [35] Cao H, Yang J, Yu J, et al. Therapeutic potential of transplanted placental mesenchymal stem cells in treating Chinese miniature pigs with acute liver failure.BMC Med. 2012;10:56. [36] Geffner LF, Santacruz P, Izurieta M, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies.Cell Transplant. 2008; 17(12):1277-1293. [37] Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200).Science. 2000;290(5497):1768-1771. [38] Jenmalm MC, Cherwinski H, Bowman EP, et al. Regulation of myeloid cell function through the CD200 receptor.J Immunol. 2006;176(1):191-199. [39] Gorczynski RM, Lee L, Boudakov I.Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation. 2005;79(9):1180-1183. [40] Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.J Immunol. 2007; 178(9):5595-5605. [41] Coles SJ, Hills RK, Wang EC, et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells.Leukemia. 2012;26(9):2146-2148. [42] Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer.Cancer Treat Rev. 2012; 38(7): 904-910. [43] Ha H, Debnath B, Neamati N.Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.Theranostics. 2017;7(6):1543-1588. |